<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF"><gtr:id>37DE1B14-06DD-4E06-AAC5-56F5BBED7FFF</gtr:id><gtr:name>MRC Toxicology Unit</gtr:name><gtr:address><gtr:line1>Hodgkin Building</gtr:line1><gtr:line2>University of Leicester</gtr:line2><gtr:line3>PO Box 138,  Lancaster Road</gtr:line3><gtr:line4>Leicester</gtr:line4><gtr:postCode>LE1 9HN</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/E61B8362-1C8D-4DBB-AB97-02E18FA4EA8E"><gtr:id>E61B8362-1C8D-4DBB-AB97-02E18FA4EA8E</gtr:id><gtr:firstName>Lia</gtr:firstName><gtr:surname>Panman</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_UP_1203%2F2"><gtr:id>F8DB3A90-DE5E-433E-A33C-F050FDB930A6</gtr:id><gtr:title>Neuronal model systems and neurotoxicity</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_UP_1203/2</gtr:grantReference><gtr:abstractText>Dopaminergic neurons that are located in the brain stem regulate diverse processes, such as voluntary movements, reward and emotions. Several diseases, including Parkinsons disease, Schizophrenia and ADHD are caused by the dysfunction of a selective group of dopaminergic neurons. For example in Parkinsons disease only the dopaminergic neurons that project to the striatum and are responsible for the initiation of the movements degenerate. Other dopaminergic neurons that are also located in the brain stem remain unaffected in Parkinsons disease. Not only in Parkinsons disease, but also in other neurodegenerative diseases like in Alzheimers and prion diseases only a selective group of neurons degenerate. Neurodegenerative diseases can be caused by a mutation in a gene that results in the production of a toxic protein or by environmental toxins. In our research we would like to understand why only a certain populations of neurons are affected by these toxic insults. We are planning to generate different neuronal cell types from embryonic stem cells and to treat these cells with neurotoxins. Analyzing the response of the cells to these neurotoxins will give us novel insights into the selective sensitivity of specific neuronal cell types, which may lead to a better understanding about the onset of the diseases.</gtr:abstractText><gtr:technicalSummary>Neurodegenerative diseases are characterized by the differential vulnerability of specific neuronal cell populations to endogenous or environmental toxic insults. For example, in Parkinsons disease specifically the dopaminergic neurons of the substantia nigra degenerate, while the ventral tegmental area neurons remain relatively spared. The reasons for the selective degeneration of neuronal cell types are still largely unknown. The research in our group aims to identify the mechanism underlying the selective vulnerability of specific neuronal cell types to neurotoxic insult. We are developing an embryonic stem cell model system that can be used to study these processes in vitro. Recently, we have shown that forced expression of neuronal lineage specific transcription factors can direct the differentiation of embryonic stem cells into several clinically relevant neuronal cell types including dopaminergic-, serotonergic- and noradrenergic neurons. Using a similar approach, we are planning to generate homogeneous populations of neuronal cell types that are affected in Parkinsons, Alzheimers and prion disease. We will compare the gene expression profile of affected neuronal cell types to neurons that are more resistant to stress. In addition, we will analyse the differential responsiveness of these cells to neurotoxicity by using chemicals or by introducing disease causing gene variants. 
 
Our second line of research is focussed on understanding the molecular mechanism underlying dopaminergic neuronal subtype specification. Dopaminergic neurons located in the midbrain are a very heterogeneous cell population and are implicated in several important neurological disorders including Parkinsons disease, Schizophrenia and anxiety. We will use embryonic stem cell derived dopaminergic neurons and mouse genetics to gain insight into processes controlling the diversification of dopaminergic neurons and the characterization of the distinct dopaminergic neuronal subtypes.
 
Ultimately, our research may contribute to the understanding of the etiology of neurodegenerative diseases and may lead to the development of novel treatments.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-12-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>1885754</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Meeting for Parkinson's disease patients and their families</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D2953921-A611-4B24-8BA4-7A451C100F3C</gtr:id><gtr:impact>We organised presentations about our research aimed to inform Parkinson's disease patients and their families about the progress and potential ways of treatment. They had the opportunity to ask questions and we showed them our research laboratories</gtr:impact><gtr:outcomeId>58c3ff4cf3fe29.77449815</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>4000000</gtr:amountPounds><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:currCode>SEK</gtr:currCode><gtr:currCountryCode>Sweden</gtr:currCountryCode><gtr:currLang>sv_SE</gtr:currLang><gtr:description>Young investigator fellowship</gtr:description><gtr:end>2016-06-02</gtr:end><gtr:fundingOrg>Swedish Research Council</gtr:fundingOrg><gtr:id>1E5BB336-504F-4DCF-9F45-CAC55184BD6F</gtr:id><gtr:outcomeId>Jmgebk9Qj7G</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-07-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>use of extrinsic factors to direct differentiation of mouse ES cells into specific dopaminergic subpopulations</gtr:description><gtr:id>EDD237FB-77A3-4F08-A034-03C1CB553B06</gtr:id><gtr:impact>Knowledge about factors required for direction of mouse ES cells into specific dopaminergic populations can be applied to iPS and human ES cell differentiations</gtr:impact><gtr:outcomeId>58c4009d1728f5.40356802</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>mouse ES cell differentiation</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>DC1BC56C-2BAB-4566-A8DD-DC832B1D2694</gtr:id><gtr:title>Transcription factor-induced lineage programming of noradrenaline and motor neurons from embryonic stem cells.</gtr:title><gtr:parentPublicationTitle>Stem cells (Dayton, Ohio)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c92057f1a77f926c0cb047699243ed3a"><gtr:id>c92057f1a77f926c0cb047699243ed3a</gtr:id><gtr:otherNames>Mong J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1066-5099</gtr:issn><gtr:outcomeId>544aabde98c082.87258434</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5D00C8F6-6C34-4504-B8D2-6AFAEA64C32B</gtr:id><gtr:title>Sox6 and Otx2 control the specification of substantia nigra and ventral tegmental area dopamine neurons.</gtr:title><gtr:parentPublicationTitle>Cell reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a62b4c4305a905c17ff10ef0c9b606b7"><gtr:id>a62b4c4305a905c17ff10ef0c9b606b7</gtr:id><gtr:otherNames>Panman L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:outcomeId>544aa9caed6ee8.57065902</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_UP_1203/2</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>CDB856E6-DF2D-4D96-88BD-1CC96FE277EF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.2  Factors relating to physical environment</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>